Immunic appoints Jason Tardio as COO

Immunic (IMUX) announced that seasoned biopharmaceutical executive, Jason Tardio, will be joining the company as COO and president, effective July 12. In the newly created role, Tardio will lead internal efforts to prepare for the potential launch of vidofludimus calcium, the company’s orally available nuclear receptor related 1 activator. Tardio will also work closely with Patrick Walsh, chief business officer, to prepare the company for a range of potential partnership outcomes for vidofludimus calcium, as well as Immunic’s other drug candidates. Tardio most recently served as COO of Ovid Therapeutics (OVID) since June 2021, after joining the company as chief commercial officer in November 2019.